scholarly journals Endometrioid adenocarcinoma presenting in a patient 18 years after hysterectomy: a potential hazard of unopposed oestrogen therapy

2009 ◽  
Vol 2009 (aug13 1) ◽  
pp. bcr0520091829-bcr0520091829 ◽  
Author(s):  
A. B. Ronga ◽  
S. K Najia ◽  
N. Sahasrabudhe ◽  
R. Prescott ◽  
F. E. Buruiana ◽  
...  
Keyword(s):  
Endometrioid Adenocarcinoma ◽  
Potential Hazard ◽  
Oestrogen Therapy ◽  
Unopposed Oestrogen

Lipoprotein(a) and postmenopausal oestrogen

1993 ◽  
Vol 129 (3) ◽  
pp. 225-228 ◽  
Author(s):  
Elizabeth Farish ◽  
Hilary A Rolton ◽  
Judith F Barnes ◽  
Colin D Fletcher ◽  
David J Walsh ◽  
...  
Keyword(s):  
Marked Effect ◽  
Density Lipoprotein ◽  
Epidemiological Studies ◽  
Oestrogen Therapy ◽  
Bilateral Oophorectomy ◽  
Short Term ◽  
Serum Samples ◽  
Lipoprotein A ◽  
Before And After ◽  
Unopposed Oestrogen

Epidemiological studies have shown that postmenopausal oestrogen therapy substantially reduces the risk of cardiovascular and cerebrovascular disease and this is partly mediated by oestrogen-associated changes in lipoproteins, particularly high-density lipoprotein. In this study, we investigated whether changes in lipoprotein(a) might help to account for the reduction in coronary heart disease and stroke associated with postmenopausal oestrogen therapy. The study group consisted of 18 women who had hysterectomy and bilateral oophorectomy at least 2 months prior to recruitment and had received no previous hormonal therapy. Serum samples were collected for measurement of lipoprotein(a) before and after 4 months of treatment with oestradiol valerate (2 mg/day). Lipoprotein(a) levels ranged from 35 to 720 mg/l (median 180 mg/l) before treatment and from 55 to 780 mg/l (median 1 30 mg/l) after oestradiol treatment and showed no consistent pattern of change. It would appear, therefore, that treatment with unopposed oestrogen in relatively low doses does not have a marked effect on lipoprotein(a), at least in the short term.

Endometriosis and atypical complex hyperplasia associated with unopposed oestrogen therapy

1994 ◽  
Vol 101 (12) ◽  
pp. 1091-1092 ◽  
Author(s):  
A. Hextall ◽  
M. A. Wilcox ◽  
M. B. Macpherson ◽  
C. S. Ubhi ◽  
I. H. Leach ◽  
...  
Keyword(s):  
Oestrogen Therapy ◽  
Unopposed Oestrogen

scholarly journals Limited evidence for a protective effect of unopposed oestrogen therapy for osteoarthritis of the hip: a systematic review

Rheumatology ◽  
2008 ◽  
Vol 48 (2) ◽  
pp. 104-112 ◽  
Author(s):  
B. M. de Klerk ◽  
D. Schiphof ◽  
F. P. M. J. Groeneveld ◽  
B. W. Koes ◽  
G. J. V. M. van Osch ◽  
...  
Keyword(s):  
Systematic Review ◽  
Protective Effect ◽  
Oestrogen Therapy ◽  
Limited Evidence ◽  
Osteoarthritis Of The Hip ◽  
Unopposed Oestrogen

Development of a Rapid Survey Method of Sampling and Analysis for Asbestos in Ambient Air

1972 ◽  
Vol 30 ◽  
pp. 630-631 ◽  
Author(s):  
R. E. Heffelfinger ◽  
C. W. Melton ◽  
D. L. Kiefer ◽  
W. M. Henry ◽  
R. J. Thompson
Keyword(s):  
Neutron Activation ◽  
Ambient Air ◽  
Survey Method ◽  
Potential Hazard ◽  
Transmission Microscopy ◽  
Comparative Analyses ◽  
Asbestos Fibers ◽  
Controlled Conditions ◽  
Unequivocal Identification ◽  
Identification And Quantification

A methodology has been developed and demonstrated which is capable of determining total amounts of asbestos fibers and fibrils in air ranging from as low as fractional nanograms per cubic meter (ng/m3) of air to several micrograms/m3. The method involves the collection of samples on an absolute filter and provides an unequivocal identification and quantification of the total asbestos contents including fibrils in the collected samples.The developed method depends on the trituration under controlled conditions to reduce the fibers to fibrils, separation of the asbestos fibrils from other collected air particulates (beneficiation), and the use of transmission microscopy for identification and quantification. Its validity has been tested by comparative analyses by neutron activation techniques. It can supply the data needed to set emissions criteria and to serve as a basis for assessing the potential hazard for asbestos pollution to the populace.

The Effects of Therapy with Oestriol Succinate and Ethinyl Oestradiol on the Haemostatic Mechanism in Post-Menopausal Women

1976 ◽  
Vol 35 (02) ◽  
pp. 403-414 ◽  
Author(s):  
Terence Davies ◽  
Gillian Fieldhouse ◽  
George P. McNicol
Keyword(s):  
Coagulation Factors ◽  
Factor Vii ◽  
Oestrogen Therapy ◽  
Qualitative And Quantitative ◽  
Lysis Activity ◽  
Menopausal Women ◽  
Increased Sensitivity ◽  
Post Menopausal ◽  
Incremental Increase ◽  
Ethinyl Oestradiol

SummaryThe effects on the haemostatic mechanism of oestrogen therapy, given to prevent bone loss in post-menopausal women, have been investigated. Oestriol succinate was given orally to 10 women at a level of 2 mg/day for 1 month and for a further 3 months with incremental increase of 2 mg each month. 6 of the 10 women were subsequently treated with 25 μg/day orally of ethinyl oestradiol. Oestriol succinate therapy resulted in a small increase in the level of factor VII, a decrease in factor VIII concentration and increased sensitivity of platelets to aggregating agents. Ethinyl oestradiol treatment resulted in much more widespread changes with marked increases in coagulation factors VII, VIII, IX and X, decreased levels of antithrombin and dramatic increases in circulating plasminogen levels and euglobulin lysis activity. The data suggested that the nature of oestrogens employed therapeutically is important in determining the qualitative and quantitative effect of oestrogen therapy on components of the haemostatic mechanism.

FEEDBACK CONTROL OF FSH IN THE MALE: ROLE OF OESTROGEN

1973 ◽  
Vol 74 (3) ◽  
pp. 449-460 ◽  
Author(s):  
Patrick C. Walsh ◽  
Ronald S. Swerdloff ◽  
William D. Odell
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Oestrogen Therapy ◽  
Serum Concentrations ◽  
Elderly Men ◽  
Normal Range ◽  
Oestrogen Treatment ◽  
Serum Lh ◽  
Higher Doses

ABSTRACT Serum follicle stimulating hormone (FSH) and luteinizing hormone (LH) were measured by radioimmunoassay in a group of elderly men following castration and oestrogen therapy. Prior to orchiectomy, mean serum concentrations of LH and FSH were within the normal range. Two days following castration, serum LH concentrations increased in all eight patients; higher levels of LH were subsequently measured in all but one patient after periods of time ranging from 49 to 210 days. Serum FSH levels, measured in three patients following castration, increased in a pattern parallel to LH changes. Ethinyl oestradiol (EOe) in doses ranging from 5 to 300 μg/day was administered to ten men who had been castrated 3 to 72 months earlier. Oestrogen treatment suppressed both LH and FSH in a parellel manner in nine of ten patients. LH was first suppressed to intact levels in one of eight patients treated with 20 μg/day of EOe, in two of six patients treated with 50 μg/day, and in one patient by 80 μg/day. FSH was not suppressed to precastration levels until 50 μg/day of EOe was administered; this dose suppressed three of six patients. Higher doses of EOe (150–300 μg/day) suppressed both LH and FSH to levels below the sensitivity of the assay. These data fail to demonstrate any differential effect of oestrogen on LH and FSH release.

Endometrioid adenocarcinoma of abdominal wall in histerectomized patient 18 years before

2018 ◽  
Author(s):  
Monica Zambrano ◽  
Richard Buendia ◽  
Nicolas Campo ◽  
Laura Lopez ◽  
Maria Alejandra Ramirez De La Cruz
Keyword(s):  
Abdominal Wall ◽  
Endometrioid Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document